Blood cell substitute to get priority review
EVANSTON - Northfield Laboratories Inc. said Tuesday that the U.S. Food and Drug Administration has accepted for filing its Biologics License Application for PolyHeme, the company's investigative human hemoglobin-based red cell substitute for the treatment of life-threatening red blood cell loss when an oxygen-carrying fluid is required and red blood cells are not available. In addition, the FDA has designated the submission for priority review, with a review goal date of April 30.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.